Los Angeles Capital Management LLC Grows Stake in Agenus Inc. (NASDAQ:AGEN)

Los Angeles Capital Management LLC grew its stake in Agenus Inc. (NASDAQ:AGENGet Rating) by 1,125.4% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 825,751 shares of the biotechnology company’s stock after acquiring an additional 758,363 shares during the quarter. Los Angeles Capital Management LLC owned about 0.29% of Agenus worth $1,602,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also made changes to their positions in AGEN. Arizona State Retirement System boosted its position in shares of Agenus by 10.7% in the 1st quarter. Arizona State Retirement System now owns 55,540 shares of the biotechnology company’s stock worth $137,000 after purchasing an additional 5,346 shares in the last quarter. Teacher Retirement System of Texas increased its stake in Agenus by 20.6% during the 1st quarter. Teacher Retirement System of Texas now owns 42,651 shares of the biotechnology company’s stock worth $105,000 after buying an additional 7,277 shares in the last quarter. Lincoln National Corp increased its stake in Agenus by 20.0% during the 1st quarter. Lincoln National Corp now owns 60,100 shares of the biotechnology company’s stock worth $148,000 after buying an additional 10,000 shares in the last quarter. U.S. Capital Wealth Advisors LLC acquired a new position in shares of Agenus during the 1st quarter worth approximately $25,000. Finally, Nisa Investment Advisors LLC boosted its holdings in shares of Agenus by 441.4% during the 2nd quarter. Nisa Investment Advisors LLC now owns 13,860 shares of the biotechnology company’s stock worth $27,000 after purchasing an additional 11,300 shares during the last quarter. 51.89% of the stock is currently owned by hedge funds and other institutional investors.

Agenus Stock Performance

Shares of AGEN opened at $2.44 on Monday. Agenus Inc. has a fifty-two week low of $1.25 and a fifty-two week high of $4.69. The company has a market capitalization of $690.92 million, a price-to-earnings ratio of 24.40 and a beta of 1.32. The firm has a 50-day simple moving average of $2.47 and a 200-day simple moving average of $2.26.

Agenus (NASDAQ:AGENGet Rating) last announced its quarterly earnings data on Tuesday, August 9th. The biotechnology company reported ($0.17) EPS for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.06. The firm had revenue of $20.93 million during the quarter, compared to the consensus estimate of $18.70 million. Agenus had a net margin of 3.07% and a return on equity of 11.65%. During the same quarter last year, the firm earned ($0.37) earnings per share. Equities research analysts forecast that Agenus Inc. will post -0.7 EPS for the current year.

Analyst Upgrades and Downgrades

AGEN has been the topic of a number of research reports. Sumitomo Mitsui Financial Group began coverage on Agenus in a research note on Wednesday, September 28th. They set an “outperform” rating and a $5.00 price target on the stock. StockNews.com started coverage on Agenus in a report on Wednesday, October 12th. They issued a “hold” rating on the stock.

About Agenus

(Get Rating)

Agenus Inc, a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.

Further Reading

Want to see what other hedge funds are holding AGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Agenus Inc. (NASDAQ:AGENGet Rating).

Institutional Ownership by Quarter for Agenus (NASDAQ:AGEN)

Receive News & Ratings for Agenus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agenus and related companies with MarketBeat.com's FREE daily email newsletter.